0000000000407639

AUTHOR

Tomislav Bulum

showing 3 related works from this author

Oral Semaglutide Versus Empagliflozin in Patients With Type 2 Diabetes Uncontrolled on Metformin: The PIONEER 2 Trial

2019

OBJECTIVE Efficacy and safety of the glucagon-like peptide 1 (GLP-1) analog oral semaglutide and the sodium–glucose cotransporter 2 inhibitor empagliflozin were compared in patients with type 2 diabetes uncontrolled on metformin. RESEARCH DESIGN AND METHODS Patients were randomized to once-daily open-label treatment with oral semaglutide 14 mg (n = 412) or empagliflozin 25 mg (n = 410) in a 52-week trial. Key end points were change from baseline to week 26 in HbA1c (primary) and body weight (confirmatory secondary). Two estimands addressed efficacy-related questions: treatment policy (regardless of trial product discontinuation or rescue medication) and trial product (on trial product with…

MaleSettore MED/09 - Medicina InternaEndocrinology Diabetes and MetabolismGlucagon-Like PeptidesAdministration OralType 2 diabeteslaw.inventionSettore MED/13 - Endocrinologia0302 clinical medicineGlucosidesRandomized controlled triallaw030212 general & internal medicineSettore MED/49 - Scienze Tecniche Dietetiche ApplicateBenzhydryl CompoundMiddle AgedMetforminMetforminTreatment Outcomediabetes mellitusDrug Therapy CombinationFemalemedicine.drugHumanAdultmedicine.medical_specialtyGlucagon-Like PeptideGlucosideUrology030209 endocrinology & metabolism03 medical and health sciencesPharmacotherapyDouble-Blind MethodWeight Loss.Diabetes mellitusWeight LossInternal MedicinemedicineEmpagliflozinHumansHypoglycemic AgentsBenzhydryl CompoundsGlycated HemoglobinAdvanced and Specialized NursingHypoglycemic Agentbusiness.industrySemaglutidemedicine.diseaseDiscontinuationDiabetes Mellitus Type 2business
researchProduct

Association between symptoms of depression, diabetes complications and vascular risk factors in four European cohorts of individuals with type 1 diab…

2020

Aims: To investigate the association between depressive symptomatology and health markers in type 1 diabetes. Methods: Four countries from the InterDiane Consortium had adopted the Finnish Diabetic Nephropathy Study protocol, including the Beck Depression Inventory (BDI). Associations between depression symptomatology, diabetes complications (diabetic nephropathy, proliferative retinopathy, major adverse cardiovascular events [MACE]) and vascular risk factors (metabolic syndrome, body mass index, glycaemic control) were investigated. Results: In a sample of 1046 participants (Croatia n = 99; Finland n = 314; Latvia n = 315; Lithuania n = 318), 13.4% displayed symptoms of depression (BDI sco…

MaleEndocrinology Diabetes and MetabolismDISEASEDiabetic nephropathy0302 clinical medicineEndocrinologyRisk FactorsGLYCEMIC CONTROLSurveys and QuestionnairesPrevalence030212 general & internal medicineDepression (differential diagnoses)2. Zero hungerDepressionGeneral MedicineMiddle AgedMetabolic syndrome3. Good healthEuropeType 1 diabetesFemaleHEALTHAdultmedicine.medical_specialty030209 endocrinology & metabolismRETINOPATHYDiabetes Complications03 medical and health sciencesInternal medicineDiabetes mellitusInternal MedicinemedicineHumansVascular DiseasesType 1 diabetesbusiness.industry616.379-008.64 [udc]Beck Depression InventoryADULTSCAREmedicine.diseaseCross-Sectional StudiesDiabetes Mellitus Type 13121 General medicine internal medicine and other clinical medicineDepression ; Diabetes complications ; Metabolic syndrome ; Type 1 diabetesDiabetes mellitus type 1 ; psychology ; Depression ; Diabetes complications ; Metabolic syndrome ; Cross-sectional studiesSelf ReportMetabolic syndromebusinessBody mass indexMace
researchProduct

Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes.

2017

BACKGROUND Degludec is an ultralong-Acting, once-daily basal insulin that is approved for use in adults, adolescents, and children with diabetes. Previous open-label studies have shown lower day-To-day variability in the glucose-lowering effect and lower rates of hypoglycemia among patients who received degludec than among those who received basal insulin glargine. However, data are lacking on the cardiovascular safety of degludec. METHODS We randomly assigned 7637 patients with type 2 diabetes to receive either insulin degludec (3818 patients) or insulin glargine U100 (3819 patients) once daily between dinner and bedtime in a double-blind, treat-To-Target, event-driven cardiovascular outco…

Insulin degludecBlood GlucoseMalemedicine.medical_treatmentDEVOTE Study GroupInsulin GlargineType 2 diabetesKaplan-Meier Estimate030204 cardiovascular system & hematologylaw.inventiondiabetes ; insulin0302 clinical medicineRandomized controlled triallawCardiovascular DiseaseGLUCOSE CONTROL11 Medical and Health SciencesRISKCOMPLICATIONSOUTCOMESIncidenceGeneral MedicineMiddle AgedInsulin Long-ActingVARIABILITYCardiovascular Diseasesdiabetes mellitusFemaleLife Sciences & BiomedicineHumanmedicine.drugmedicine.medical_specialty030209 endocrinology & metabolismAged; Blood Glucose; Cardiovascular Diseases; Diabetes Mellitus Type 2; Double-Blind Method; Female; Humans; Hypoglycemia; Hypoglycemic Agents; Incidence; Insulin Glargine; Insulin Long-Acting; Kaplan-Meier Estimate; Male; Middle Aged; Medicine (all)HypoglycemiaBedtimeArticleEVENTS03 medical and health sciencesHYPOGLYCEMIAMedicine General & InternalDouble-Blind MethodInternal medicineDiabetes mellitusGeneral & Internal MedicinemedicineHumansHypoglycemic AgentsIntensive care medicineMETAANALYSISAgedScience & TechnologyHypoglycemic AgentInsulin glarginebusiness.industryInsulinmedicine.diseaseDiabetes Mellitus Type 2businessBASAL INSULIN
researchProduct